Spyre Therapeutics Inc expected to post a loss of 99 cents a share - Earnings Preview

Spyre Therapeutics

26/02/2025 21:07

Spyre Therapeutics Inc SYRE.OQ SYRE.O is expected to show a rise in quarterly revenue when it reports  results on February 28 (estimated) for the period ending December 31 2024

The Waltham Massachusetts-based  company is expected to report revenue of $2.1 million, according to the mean estimate from 10 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Spyre Therapeutics Inc is for a loss of 99 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Spyre Therapeutics Inc is $65.00‚Äč, above‚Äč its last closing price of $20.65. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.80
-0.82
-1.36
Missed
-65
Jun. 30 2024
-1.02
-0.95
-0.86
Beat
9.5
Mar. 31 2024
-1.18
-1.17
-1.20
Missed
-2.9‚Äč
Dec. 31 2023
-0.52
-0.78
-4.05
Missed
-416.4
‚Äč‚ÄčSep. 30 2023
-0.68
-0.84
-9.34
Missed
-1,005.3
Jun. 30 2023
-4.50
-4.50
-41.50
Missed
-822.2‚Äč
Mar. 31 2023
-4.75
-4.50
-5.00
Missed
-11.1
Dec. 31 2022
-5.04
-5.00
-4.50
Beat
10

This summary was machine generated February 26 at 21:07 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)